| Biomarker ID | 515 |
| PMID | 20171670 |
| Year | 2010 |
| Biomarker | p2PSA ([-2]isoform of proenzyme prostate specific antigen) |
| Biomarker Basis | Concentration Based (ng/ml) |
| Biomolecule | Protein |
| Source | Serum |
| Subjects | Humans |
| Regulation | Upregulated in PCa |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways include:-ID regulation of gene expression,Prostate cancer, Androgen receptor proteolysis and transcription regulation, Androgen receptor signaling, proteolysis, and transcription regulation, Insulin-like growth factor (IGF) activity regulation by insulin-like growth factor binding proteins (IGFBPs) |
| Experiment | Prostate Cancer Vs Benign Sample |
| Type of Biomarker | Diagnostic |
| Cohort | 2034 men were screened for prostate cancer, and 322 were reccomended for biopsy. Out of these, 74 men complied out of which, 3 had a total PSA of 2.5 to 10 ng/ml and nonsuspicious DRE. |
| Senstivity | 88.5% |
| Specificity | 4860% |
| AUC | 0.76 |
| Accuracy | NA |
| Level Of Significance | p = 0.0006 |
| Method Used | Beckman Coulter ACCESS® 2 immunoassay |
| Clinical | No |
| Remarks | p2PSA provides improved discrimination between prostate cancer and benign disease in screened men with a prostate specific antigen of 2.5 to 10 ng/ml and a negative digital rectal examination. |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | KLK3 |